PhenixFIN Corporation Prices Public Offering of $50.0 million of 5.25% Notes Due 2028

About this update from Phenixfin Corporation

[{"type":"text","content":"NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- PhenixFIN Corporation (NASDAQ: PFX) (the “Company” or “PhenixFIN”) today announced that it priced a public offering of $50.0 million aggregate principal amount of 5.25% Notes due 2028 (the “Notes”). The Notes will mature on November 1, 2028, and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after November 1, 2023. The Notes will bear interest at a rate of 5.25% per year payable quarterly on February 1, May 1, August 1 and November 1 of each year, beginning February 1, 2022. The Company also granted the underwriters a 30-day option to purchase up to an additional $7.5 million in aggregate principal amount of Notes to cover overallotments, if any. The Company expects to list the Notes on the Nasdaq Global Market under the trading symbol “PFXNZ” within 30 days of issuance. Oppenheimer & Co. Inc., B. Riley Securities, Inc., BTIG, LLC, Janney Montgomery Scott LLC and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers for this offering. The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered on or about November 15, 2021. The Company intends to use the net proceeds from this offering to redeem a portion of the outstanding principal amount of its 6.125% Notes due 2023. Investors are advised to carefully consider the investment objectives, risks and charges and expenses of the Company before investing. The preliminary prospectus supplement, dated November 8, 2021, and the accompanying prospectus, dated October 19, 2021, which have been filed with the U.S. Securities and Exchange Commission (the “SEC”), contain this and other information about the Company and should be read carefully before investing. The offering is being conducted as a public offering under the Company’s effective shelf registration filed with the SEC (File No. 333–258913). To obtain a copy of the preliminary prospectus supplement for this offering and the accompanying prospectus, please contact: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 23rd Floor, New York, NY 10004 or by email at [email protected]. The information in the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may change...

More updates from Phenixfin Corporation